A Phase 3 interventional study of Placebo and Upadacitinib in Psoriatic Arthritis, sponsored by AbbVie. Completed at 165 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-11.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Arthritis, Psoriatic by AbbVie — 4 open to participants now, 6 under way, 3 of them phase 3. Arthritis, Psoriatic · AbbVie.
Among the 34 studies in Arthritis, Psoriatic by AbbVie, this one is the 3rd largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2017, is one of 5 in phase 3, and was the 21st registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.
Browse Arthritis, Psoriatic studies →4 of the 34 studies in Arthritis, Psoriatic by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Canada, Czechia and 3 more countries
Ages 18+
AbbVie · Sites in Argentina, Austria, Belgium and 12 more countries
Ages 18–75
AbbVie · Sites in United States, Australia, Canada and 6 more countries
Ages 5–17
AbbVie · Sites in United States
Women only
By country, each count listing its studies:
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 642 is above the median of 145 across 336 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 246 across the 11 interventional studies, 474 across the 22 observational. Of the 27 that completed or were terminated, 19 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 34 studies in Arthritis, Psoriatic by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3 multicenter study that included two periods. Period 1 was designed to compare the safety, tolerability, and efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo in participants with moderately to severely active Psoriatic Arthritis (PsA) who had an inadequate response to Biological Disease Modifying Anti-Rheumatic Drug (bDMARDs). Period 2 evaluated the safety, tolerability and efficacy of upadacitinib 15 mg QD and 30 mg QD in subjects with PsA who completed Period 1.
The study included a 35-day screening period; a 56-week blinded period which included 24 weeks of randomized, double-blind, parallel-group, placebo-controlled treatment followed by an additional 32 weeks of treatment blinded to the dose of upadacitinib (Period 1); a long-term extension period of up to a total treatment duration of up to approximately 3 years (Period 2); and a 30-day follow-up call or visit.
All participants in Period 1 who were randomized to receive Placebo up to 24 weeks were pooled for the assessment of all outcome measures. All participants receiving upadacitinib 30 mg QD during Period 2 were switched to upadacitinib 15 mg QD following a protocol amendment and were pooled for AE reporting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Administered once daily.
Drug: Upadacitinib
Administered once daily.
Drug: Placebo · Drug: Upadacitinib
Administered once daily.
Drug: Upadacitinib
Administered once daily.
Drug: Placebo · Drug: Upadacitinib
Oral tablet
Oral tablet
Also known as: ABT-494
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.
Time frame: Baseline and Week 12
Percentage of Participants Achieving a Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at Least a 2-point Improvement From Baseline (sIGA 0/1) at Week 16
The sIGA is a 5 point scale ranging from 0 to 4, based on the investigator's assessment of the average elevation, erythema, and scaling of all psoriatic lesions at the current visit. A lower score indicates less severe psoriasis (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe).
Time frame: Baseline and Week 16
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response at Week 16
PASI is a composite score based on the percentage of the body surface area (BSA) affected by psoriasis and the intensity of erythema (reddening), induration (thickening or hardening of the skin), and desquamation (peeling of the skin) of lesions assessed at 4 anatomic sites (head, upper extremities, trunk, and lower extremities). At each location, the percentage of BSA involvement is assigned a score from 0 (no involvement) to 6 (90% to 100% involvement), and erythema, induration, and desquamation are scored on a scale from 0 (no symptoms) to 4 (very marked). The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from Baseline in PASI score.
Time frame: Baseline and Week 16
Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12
The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from Baseline score indicates an improvement.
Time frame: Baseline and Week 12
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 12
The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days, including physical fatigue (e.g., I feel tired), functional fatigue (e.g., trouble finishing things), emotional fatigue (e.g., frustration), and social consequences of fatigue (e.g., limits social activity). Participants respond to the questions on a scale from 0 'not at all' to 4 'very much'. The FACIT Fatigue score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue subscale score ranges from 0 to 52, where higher scores represent less fatigue. A positive change from Baseline indicates improvement.
Time frame: Baseline and Week 12
Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 24
A participant was classified as achieving MDA if 5 of the following 7 criteria were met: * Tender joint count (out of 68 joints) ≤ 1 * Swollen joint count (out of 66 joints) ≤ 1 * PASI score ≤ 1 (score ranges from 0 - 72) or percent BSA involved with psoriasis ≤ 3% * Patient's assessment of pain ≤ 1.5 (NRS from 0 to 10) * Patient's Global Assessment of disease activity ≤ 2 (NRS from 0 to 10) * HAQ-DI score ≤ 0.5 (index score ranges from 0 to 3) * Leeds Enthesitis Index ≤ 1 (assesses the presence or absence of enthesitis at 3 bilateral sites, with an overall score range from 0 to 6)
Time frame: Week 24
Change From Baseline in Self-Assessment of Psoriasis Symptoms (SAPS) Score at Week 16
The SAPS is an 11-item self-assessment of psoriasis symptoms that includes questions on: pain, itching, redness, scaling, flaking, bleeding, burning, stinging, tenderness, pain due to skin cracking, and joint pain. Each item is scored from 0 to 10, with 0 being least severe and 10 being most severe. The total score is generated by summing the 11 items and ranges from 0 to 110 (worst). A negative change from Baseline in the total score indicates improvement.
Time frame: Baseline and Week 16
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 12
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
Time frame: Baseline and Week 2
This study was conducted at 123 sites in 16 countries (Belgium, Brazil, Canada, Chile, Czech Republic, France, Greece, Hungary, Italy, Japan, Netherlands, New Zealand, Portugal, Spain, United Kingdom, United States \[including Puerto Rico\]). Adults with active psoriatic arthritis (PsA) and a history of inadequate response or intolerance to at least one biologic disease modifying anti-rheumatic drug (bDMARD) were enrolled.
| Milestone | Placebo / Upadacitinib 15 mg | Placebo / Upadacitinib 30 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Started | 106 | 106 | 211 | 219 |
| Received study drug | 106 | 106 | 211 | 218 |
| Completed week 24 | 81 | 92 | 192 | 195 |
| Completed | 69 | 77 | 167 | 166 |
| Not completed | 37 | 29 | 44 | 53 |
| Withdrew: Adverse event | 7 | 7 | 12 | 14 |
| Withdrew: Withdrawal by subject | 18 | 9 | 10 | 17 |
| Withdrew: Lost to follow-up | 4 | 4 | 6 | 8 |
| Withdrew: Lack of efficacy | 6 | 7 | 12 | 6 |
| Withdrew: Other | 2 | 2 | 4 | 7 |
| Withdrew: One participant did not qualify per inclusion/exclusion criteria and discontinued prior to treatment | 0 | 0 | 0 | 1 |
| Milestone | Placebo / Upadacitinib 15 mg | Placebo / Upadacitinib 30 mg | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|---|
| Started | 69 | 77 | 167 | 165 |
| Switched to 15mg qd upa dosing in period 2 | 0 | 28 | 0 | 59 |
| Completed | 55 | 55 | 131 | 126 |
| Not completed | 14 | 22 | 36 | 39 |
| Withdrew: Adverse event | 4 | 7 | 10 | 10 |
| Withdrew: Withdrawal by subject | 3 | 7 | 13 | 16 |
| Withdrew: Lost to follow-up | 2 | 2 | 3 | 5 |
| Withdrew: Lack of efficacy | 2 | 4 | 7 | 4 |
| Withdrew: Covid-19 infection | 0 | 0 | 1 | 0 |
| Withdrew: Other | 3 | 2 | 2 | 4 |
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
| percentage of participants | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | 24.1 (18.3 to 29.8) | 56.9 (50.2 to 63.6) | 63.8 (57.4 to 70.1) |
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from Baseline in the overall score indicates improvement.
| score on a scale | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 | -0.10 (-0.16 to -0.03) | -0.30 (-0.37 to -0.24) | -0.41 (-0.47 to -0.35) |
The sIGA is a 5 point scale ranging from 0 to 4, based on the investigator's assessment of the average elevation, erythema, and scaling of all psoriatic lesions at the current visit. A lower score indicates less severe psoriasis (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe).
| percentage of participants | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Percentage of Participants Achieving a Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at Least a 2-point Improvement From Baseline (sIGA 0/1) at Week 16 | 9.2 (4.8 to 13.6) | 36.8 (29.6 to 44.1) | 40.2 (32.7 to 47.7) |
PASI is a composite score based on the percentage of the body surface area (BSA) affected by psoriasis and the intensity of erythema (reddening), induration (thickening or hardening of the skin), and desquamation (peeling of the skin) of lesions assessed at 4 anatomic sites (head, upper extremities, trunk, and lower extremities). At each location, the percentage of BSA involvement is assigned a score from 0 (no involvement) to 6 (90% to 100% involvement), and erythema, induration, and desquamation are scored on a scale from 0 (no symptoms) to 4 (very marked). The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from Baseline in PASI score.
| percentage of participants | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response at Week 16 | 16.0 (9.7 to 22.3) | 52.3 (43.7 to 60.9) | 56.5 (48.0 to 65.0) |
The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from Baseline score indicates an improvement.
| score on a scale | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12 | 1.62 (0.58 to 2.67) | 5.15 (4.14 to 6.15) | 7.06 (6.07 to 8.06) |
The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days, including physical fatigue (e.g., I feel tired), functional fatigue (e.g., trouble finishing things), emotional fatigue (e.g., frustration), and social consequences of fatigue (e.g., limits social activity). Participants respond to the questions on a scale from 0 'not at all' to 4 'very much'. The FACIT Fatigue score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue subscale score ranges from 0 to 52, where higher scores represent less fatigue. A positive change from Baseline indicates improvement.
| score on a scale | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 12 | 1.3 (0.1 to 2.5) | 5.0 (3.8 to 6.1) | 6.1 (4.9 to 7.2) |
A participant was classified as achieving MDA if 5 of the following 7 criteria were met: * Tender joint count (out of 68 joints) ≤ 1 * Swollen joint count (out of 66 joints) ≤ 1 * PASI score ≤ 1 (score ranges from 0 - 72) or percent BSA involved with psoriasis ≤ 3% * Patient's assessment of pain ≤ 1.5 (NRS from 0 to 10) * Patient's Global Assessment of disease activity ≤ 2 (NRS from 0 to 10) * HAQ-DI score ≤ 0.5 (index score ranges from 0 to 3) * Leeds Enthesitis Index ≤ 1 (assesses the presence or absence of enthesitis at 3 bilateral sites, with an overall score range from 0 to 6)
| percentage of participants | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 24 | 2.8 (0.6 to 5.1) | 25.1 (19.3 to 31.0) | 28.9 (22.9 to 34.9) |
The SAPS is an 11-item self-assessment of psoriasis symptoms that includes questions on: pain, itching, redness, scaling, flaking, bleeding, burning, stinging, tenderness, pain due to skin cracking, and joint pain. Each item is scored from 0 to 10, with 0 being least severe and 10 being most severe. The total score is generated by summing the 11 items and ranges from 0 to 110 (worst). A negative change from Baseline in the total score indicates improvement.
| score on a scale | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Change From Baseline in Self-Assessment of Psoriasis Symptoms (SAPS) Score at Week 16 | -1.5 (-4.7 to 1.8) | -24.4 (-27.5 to -21.2) | -29.7 (-32.8 to -26.6) |
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
| percentage of participants | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 | 4.7 (1.9 to 7.6) | 31.8 (25.5 to 38.0) | 37.6 (31.2 to 44.0) |
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
| percentage of participants | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12 | 0.5 (0.0 to 1.4) | 8.5 (4.8 to 12.3) | 16.5 (11.6 to 21.4) |
Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).
| percentage of participants | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg |
|---|---|---|---|
| Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 2 | 10.8 (6.7 to 15.0) | 32.7 (26.4 to 39.0) | 33.5 (27.2 to 39.8) |
Collected over All-cause mortality and adverse event tables include events reported from enrollment to the end of the study. For Period 1, the median time participants were followed was: 414 days (15mg Upa); 413 days (30mg Upa); 190 days (Pooled Placebo ICF to week 24); 415 days (Pbo 15mg Upa); and 415 days (Pbo 30mg Upa). For Period 2, the median time participants were followed was: 712 days (15mg Upa); 701 days (30mg Upa); 703 days (Pbo 15mg Upa); 672 days (Pbo 30mg Upa); and 223 days (Switched to 15mg Upa).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period 1: Upadacitinib 15 mg (ICF to Week 56) | 0/211 (0%) | 22/211 (10.4%) | 111/211 (52.6%) |
| Period 1: Upadacitinib 30 mg (ICF to Week 56) | 0/219 (0%) | 25/219 (11.4%) | 139/219 (63.5%) |
| Period 1: Pooled Placebo (ICF to Week 24) | 1/212 (0.5%) | 5/212 (2.4%) | 87/212 (41%) |
| Period 1: Placebo / Upadacitinib 15 mg (Week 24 to Week 56) | 0/79 (0%) | 3/79 (3.8%) | 32/79 (40.5%) |
| Period 1: Placebo / Upadacitinib 30 mg (Week 24 to Week 56) | 0/90 (0%) | 6/90 (6.7%) | 34/90 (37.8%) |
| Period 2: Upadacitinib 15 mg (Week 56 to EOS) | 5/167 (3%) | 24/167 (14.4%) | 111/167 (66.5%) |
| Period 2: Upadacitinib 30 mg (Week 56 to EOS) | 0/165 (0%) | 19/165 (11.5%) | 99/165 (60%) |
| Period 2: Placebo / Upadacitinib 15 mg (Week 56 to Week EOS) | 0/69 (0%) | 7/69 (10.1%) | 42/69 (60.9%) |
| Period 2: Placebo / Upadacitinib 30 mg (Week 56 to EOS) | 2/77 (2.6%) | 12/77 (15.6%) | 49/77 (63.6%) |
| Period 2: Pooled Upadacitinib Groups Who Switched From 30 mg to 15 mg in Period 2 | 0/87 (0%) | 5/87 (5.7%) | 34/87 (39.1%) |
| Event | Period 1: Upadacitinib 15 mg (ICF to Week 56) | Period 1: Upadacitinib 30 mg (ICF to Week 56) | Period 1: Pooled Placebo (ICF to Week 24) | Period 1: Placebo / Upadacitinib 15 mg (Week 24 to Week 56) | Period 1: Placebo / Upadacitinib 30 mg (Week 24 to Week 56) | Period 2: Upadacitinib 15 mg (Week 56 to EOS) | Period 2: Upadacitinib 30 mg (Week 56 to EOS) | Period 2: Placebo / Upadacitinib 15 mg (Week 56 to Week EOS) | Period 2: Placebo / Upadacitinib 30 mg (Week 56 to EOS) | Period 2: Pooled Upadacitinib Groups Who Switched From 30 mg to 15 mg in Period 2 |
|---|---|---|---|---|---|---|---|---|---|---|
| PNEUMONIAInfections and infestations | 3/211 | 3/219 | 0/212 | 1/79 | 0/90 | 0/167 | 2/165 | 0/69 | 1/77 | 2/87 |
| COVID-19Infections and infestations | 0/211 | 0/219 | 0/212 | 0/79 | 0/90 | 3/167 | 0/165 | 1/69 | 0/77 | 0/87 |
| GASTRITISGastrointestinal disorders | 0/211 | 0/219 | 0/212 | 0/79 | 0/90 | 0/167 | 0/165 | 1/69 | 0/77 | 0/87 |
| CHOLELITHIASISHepatobiliary disorders | 0/211 | 0/219 | 0/212 | 0/79 | 0/90 | 1/167 | 0/165 | 1/69 | 0/77 | 1/87 |
| ABSCESSInfections and infestations | 0/211 | 0/219 | 0/212 | 0/79 | 0/90 | 0/167 | 0/165 | 1/69 | 0/77 | 0/87 |
| LIVER ABSCESSInfections and infestations | 0/211 | 0/219 | 0/212 | 0/79 | 0/90 | 0/167 | 0/165 | 1/69 | 0/77 | 0/87 |
| POST PROCEDURAL BILE LEAKInjury, poisoning and procedural complications | 0/211 | 0/219 | 0/212 | 0/79 | 0/90 | 0/167 | 0/165 | 1/69 | 0/77 | 0/87 |
| DIABETIC KETOACIDOSISMetabolism and nutrition disorders | 0/211 | 0/219 | 0/212 | 0/79 | 0/90 | 0/167 | 0/165 | 1/69 | 0/77 | 0/87 |
| BACK PAINMusculoskeletal and connective tissue disorders | 0/211 | 0/219 | 0/212 | 0/79 | 0/90 | 0/167 | 0/165 | 1/69 | 0/77 | 0/87 |
| DIZZINESSNervous system disorders | 1/211 | 0/219 | 0/212 | 0/79 | 0/90 | 0/167 | 0/165 | 1/69 | 0/77 | 0/87 |
| Event | Period 1: Upadacitinib 15 mg (ICF to Week 56) | Period 1: Upadacitinib 30 mg (ICF to Week 56) | Period 1: Pooled Placebo (ICF to Week 24) | Period 1: Placebo / Upadacitinib 15 mg (Week 24 to Week 56) | Period 1: Placebo / Upadacitinib 30 mg (Week 24 to Week 56) | Period 2: Upadacitinib 15 mg (Week 56 to EOS) | Period 2: Upadacitinib 30 mg (Week 56 to EOS) | Period 2: Placebo / Upadacitinib 15 mg (Week 56 to Week EOS) | Period 2: Placebo / Upadacitinib 30 mg (Week 56 to EOS) | Period 2: Pooled Upadacitinib Groups Who Switched From 30 mg to 15 mg in Period 2 |
|---|---|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 0/211 | 0/219 | 0/212 | 0/79 | 0/90 | 21/167 | 12/165 | 7/69 | 7/77 | 14/87 |
| NASOPHARYNGITISInfections and infestations | 24/211 | 29/219 | 17/212 | 5/79 | 6/90 | 14/167 | 12/165 | 7/69 | 6/77 | 5/87 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 22/211 | 29/219 | 10/212 | 6/79 | 2/90 | 15/167 | 9/165 | 5/69 | 6/77 | 3/87 |
| PSORIATIC ARTHROPATHYMusculoskeletal and connective tissue disorders | 13/211 | 7/219 | 11/212 | 2/79 | 3/90 | 12/167 | 16/165 | 9/69 | 8/77 | 8/87 |
| URINARY TRACT INFECTIONInfections and infestations | 19/211 | 16/219 | 12/212 | 4/79 | 4/90 | 17/167 | 14/165 | 8/69 | 9/77 | 3/87 |
| HYPERTENSIONVascular disorders | 8/211 | 10/219 | 10/212 | 4/79 | 3/90 | 19/167 | 11/165 | 5/69 | 7/77 | 1/87 |
| BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations | 9/211 | 22/219 | 4/212 | 2/79 | 4/90 | 13/167 | 9/165 | 5/69 | 6/77 | 2/87 |
| BRONCHITISInfections and infestations | 17/211 | 15/219 | 5/212 | 5/79 | 4/90 | 15/167 | 8/165 | 6/69 | 4/77 | 2/87 |
| HERPES ZOSTERInfections and infestations | 8/211 | 13/219 | 2/212 | 2/79 | 5/90 | 10/167 | 13/165 | 3/69 | 5/77 | 1/87 |
| SINUSITISInfections and infestations | 8/211 | 9/219 | 9/212 | 3/79 | 2/90 | 7/167 | 7/165 | 2/69 | 6/77 | 0/87 |
The Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|
| Mean | 54.1 ± 11.53 | 53.0 ± 12.02 | 53.0 ± 11.94 | 53.4 ± 11.83 |
| Sex: Female, Male(Participants) | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|
| Female | 120 | 113 | 115 | 348 |
| Male | 92 | 98 | 103 | 293 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 53 | 36 | 50 | 139 |
| Not Hispanic or Latino | 159 | 175 | 168 | 502 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|
| White | 186 | 183 | 196 | 565 |
| Black or African American | 7 | 5 | 5 | 17 |
| American Indian/Alaska Native | 0 | 3 | 0 | 3 |
| Native Hawaiian or other Pacific Islander | 1 | 1 | 1 | 3 |
| Asian | 17 | 19 | 16 | 52 |
| Multiple | 1 | 0 | 0 | 1 |
| Extent of Psoriasis(Participants) | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|
| < 3% BSA | 81 | 81 | 87 | 249 |
| ≥ 3% BSA | 131 | 130 | 131 | 392 |
| Number of Prior Failed Biologic DMARDs(Participants) | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|
| 0 bDMARDS | 18 | 16 | 17 | 51 |
| 1 bDMARD | 135 | 126 | 130 | 391 |
| 2 bDMARDS | 35 | 35 | 46 | 116 |
| ≥ 3 bDMARDS | 24 | 34 | 25 | 83 |
| Duration of Psoriatic Arthritis Symptoms(years) | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|
| Mean | 14.6 ± 11.70 | 12.2 ± 8.81 | 13.3 ± 10.84 | 13.4 ± 10.54 |
| Duration of PsA Diagnosis(years) | Placebo | Upadacitinib 15 mg | Upadacitinib 30 mg | Total |
|---|---|---|---|---|
| Mean | 11.0 ± 10.33 | 9.6 ± 8.36 | 9.7 ± 8.71 | 10.1 ± 9.18 |
7 further baseline measures are reported on the registry.
Showing the first 100 of 165 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from May 2017 to primary completion in Jul 2019, 26 months.
Results were first posted in Jan 2022, 2 years 6 months after primary completion. A results delay was requested in Jul 2020.
Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 26 months is close to that.
Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Upadacitinib